Qube Research & Technologies (QRT)’s Pliant Therapeutics PLRX Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio PLRX Stock Details PLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$13.8K	Sell	10,966 -4,459	-29%	-$5.63K	﹤0.01%	3308
2025 Q4	$18.8K	Sell	15,425 -34,090	-69%	-$51.2K	﹤0.01%	3390
2025 Q3	$73.3K	Sell	49,515 -102,147	-67%	-$156K	﹤0.01%	3117
2025 Q2	$176K	Buy	+151,662	New	+$214K	﹤0.01%	2935
2023 Q3	–	Sell	-74,025	Closed	-$1.34M	–	4280
2023 Q2	$1.34M	Sell	74,025 -101,850	-58%	-$2.41M	﹤0.01%	1188
2023 Q1	$4.68M	Buy	175,875 +98,805	+128%	+$2.81M	0.02%	695
2022 Q4	$1.49M	Buy	77,070 +50,169	+186%	+$1.05M	0.01%	1051
2022 Q3	$562K	Buy	26,901 +13,442	+100%	+$257K	﹤0.01%	1426
2022 Q2	$108K	Buy	+13,459	New	+$86.2K	﹤0.01%	1921

Other funds holding PLRX

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

MAM

Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Qube Research & Technologies (QRT)'s PLRX Position: Q1 2026 in Review

Qube Research & Technologies (QRT) reduced its Pliant Therapeutics (PLRX) stake by 29% in Q1 2026, selling an estimated $5.63K and leaving 10,966 shares worth $13.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3308.

Qube Research & Technologies (QRT) first reported a position in PLRX in Q2 2022 and has held it in 9 quarters since. The position peaked at $4.68M in Q1 2023. 91 funds tracked by Wall St. Rank hold PLRX as of Q1 2026.

Qube Research & Technologies (QRT) held 10,966 shares of Pliant Therapeutics worth $13.8K as of Q1 2026.
Qube Research & Technologies (QRT) sold 4,459 Pliant Therapeutics shares in Q1 2026, an estimated $5.63K.
Pliant Therapeutics made up ﹤0.01% of Qube Research & Technologies (QRT)'s portfolio in Q1 2026, its #3308 holding.
Qube Research & Technologies (QRT) first reported a position in Pliant Therapeutics in Q2 2022 and has held it in 9 quarters since.
Qube Research & Technologies (QRT)'s Pliant Therapeutics position peaked at $4.68M in Q1 2023.
91 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q1 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q1 2026, filed 15 May 2026.